Wanted pages

From Glioblastoma Treatments
Jump to navigationJump to search

List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.

Showing below up to 50 results in range #251 to #300.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. No known toxic side effects‏‎ (1 link)
  2. Not applicable; current recommendations favor omega-3 fatty acids for potential CNS benefits‏‎ (1 link)
  3. Not applicable; current research focuses on biochemical effects and prevention metrics like PSA doubling time in prostate cancer‏‎ (1 link)
  4. Not applicable; current research has not progressed to detailed assessments of progression-free survival in cancer patients.‏‎ (1 link)
  5. Not applicable; current research is primarily in preclinical stages focusing on cellular mechanisms‏‎ (1 link)
  6. Not applicable; direct impacts on progression-free survival in cancer patients are not yet established‏‎ (1 link)
  7. Not applicable; emphasis on omega-3 fatty acids due to better CNS penetration and cost-effectiveness‏‎ (1 link)
  8. Not applicable; preclinical focus does not include progression-free survival metrics‏‎ (1 link)
  9. Not applicable; preclinical studies do not measure overall survival‏‎ (1 link)
  10. Not applicable; studies are ongoing to determine its effect on disease progression in preclinical models‏‎ (1 link)
  11. Not applicable; studies focus on biomolecular impacts rather than direct survival outcomes‏‎ (1 link)
  12. Not applicable; studies focus on cellular and symptom management rather than direct survival outcomes‏‎ (1 link)
  13. Not applicable; the majority of evidence is from preclinical studies, without detailed human data on overall survival impacts.‏‎ (1 link)
  14. Not detailed; dendritic cell vaccines are generally well-tolerated with mild side effects.‏‎ (1 link)
  15. Not directly specified; chloroquine shown to induce remission rates without increasing adverse events significantly‏‎ (1 link)
  16. Not explicitly detailed; similar immunotherapy treatments often include flu-like symptoms, injection site reactions, fatigue‏‎ (1 link)
  17. Not extensively documented; generally considered safe with potential for mild digestive upset‏‎ (1 link)
  18. Not fully established; dramatic and rapid tumor regression observed in initial patients‏‎ (1 link)
  19. Not specifically documented; as a naturally occurring compound in fruits and nuts, it is generally considered safe‏‎ (1 link)
  20. Not specifically documented; clinical trials have shown mixed results, with some indicating significant benefit when added to standard chemotherapy protocols‏‎ (1 link)
  21. Not specifically documented; research highlights increased survival and potential for enhanced treatment efficacy‏‎ (1 link)
  22. Not specifically mentioned; dietary supplements like GLA are generally well-tolerated‏‎ (1 link)
  23. Not specifically mentioned; research primarily focused on overall survival and symptomatic relief‏‎ (1 link)
  24. Not specified, typical of nitrosoureas may include myelosuppression, nausea, and liver enzyme elevation‏‎ (1 link)
  25. Not specified; efficacy primarily reported in terms of overall survival and response rates in available studies‏‎ (1 link)
  26. Not specified; ongoing studies for cancer-specific outcomes‏‎ (1 link)
  27. Not specified; research focuses on enhancing therapeutic profiles while minimizing toxicity‏‎ (1 link)
  28. Not specified in provided details‏‎ (1 link)
  29. Not specified in the recent analysis‏‎ (1 link)
  30. Ongoing optimization of thalidomide analogues‏‎ (1 link)
  31. Ongoing research and clinical trials‏‎ (1 link)
  32. Phase-2 and Phase-3 trials‏‎ (1 link)
  33. Phase 1‏‎ (1 link)
  34. Phase 1 (INCIPIENT trial among others)‏‎ (1 link)
  35. Phase 1 and Phase 2 trials‏‎ (1 link)
  36. Phase 1b/2a data shows PFS6 of 44% in newly diagnosed glioblastoma and 31% in recurrent cases.‏‎ (1 link)
  37. Phase 2‏‎ (1 link)
  38. Phase 2 (based on ongoing and completed trials for various cancer types)‏‎ (1 link)
  39. Phase 2 (ongoing evaluation in GBM AGILE for various GBM subtypes)‏‎ (1 link)
  40. Phase 2 and 3 (for different cancers); early-stage trials for GBM‏‎ (1 link)
  41. Phase 2 trial for glioblastoma with Sativex combined with temozolomide‏‎ (1 link)
  42. Phase 3 (EF-14 Trial); Phase 3 TRIDENT trial ongoing‏‎ (1 link)
  43. Phase 3 (Germany)‏‎ (1 link)
  44. Phase 3 for ALS and DCM, Phase 3-ready for Progressive MS, Phase 2 for glioblastoma, Long COVID, and substance use disorder‏‎ (1 link)
  45. Phase I/II‏‎ (1 link)
  46. Phase I/II trials in combination with other therapies‏‎ (1 link)
  47. Phase III‏‎ (1 link)
  48. Phase III (Europe for Gliadel)‏‎ (1 link)
  49. Phase III ACT IV trial did not show a significant increase in OS; however, a Phase II trial (ReACT) in recurrent GBM showed improved outcomes with bevacizumab‏‎ (1 link)
  50. Phase III for newly diagnosed GBM was discontinued; Phase II for recurrent GBM showed promising results‏‎ (1 link)

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Special:WantedPages"